skip to Main Content

Eryaspase/Chemo Misses OS End Point in Second-Line Pancreatic Cancer, But Warrants Further Investigation

Newsfeed image, light gray text on dark gray background
Although the addition of eryaspase to chemotherapy improved overall survival (OS) over chemotherapy alone in patients with metastatic pancreatic cancer, the difference in benefit was not found to be statistically significant, missing the primary end point of the phase 3 TRYbeCA-1 trial (NCT03665441).

Top-line data demonstrated that the median OS in the intent-to-treat population was 7.5 months (95% CI, 6.5-8.3) with eryaspase and chemotherapy vs 6.7 months (95% CI, 5.4-7.5) with chemotherapy alone (HR, 0.92; 95% CI, 0.76-1.11; = .375). Read more. . . 


Back To Top